

1. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brünner N, Chan DW, Babaian R, Bast RC Jr, Dowell B, Esteva FJ, Haglund C, Harbeck N, Hayes DF, Holten-Andersen M, Klee GG, Lamerz R, Looijenga LH, Molina R, Nielsen HJ, Rittenhouse H, Semjonow A, Shih IeM, Sibley P, Sölétormos G, Stephan C, Sokoll L, Hoffman BR, Diamandis EP; National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. *Clin Chem*. 2008 Dec;54(12):e11-79.
2. Duffy MJ, Bonfrer JM, Kulpa J, Rustin GJ, Soletormos G, Torre GC, Tuxen MK, Zwirner M. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. *Int J Gynecol Cancer*. 2005 Sep-Oct;15(5):679-91.
3. Bast RC, Fenney M, Lazarus H, Nadles LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. *J Clin Invest* 1981;68:1331-1337.
4. Bast RC, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR, Knapp RC. A Radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. *N Engl J Med* 1983;309:883-887.
5. Jacobs I, Bast RC. The CA125 tumour-associated antigen: A review of the literature. *Hum Reprod* 1989;4:1-12.
6. Nustad K, Bast RC Jr, Brien TJ, Nilsson O, Seguin P, Suresh MR, Saga T, Nozawa S, Børner OP, de Bruijn HW, Nap M, Vitali A, Gadnell M, Clark J, Shigemasa K, Karlsson B, Kreutz FT, Jette D, Sakahara H, Endo K, Paus E, Warren D, Hammarström S, Kenemans P, Hilgers J. Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: first report from the ISOBM TD-1 workshop. *International Society for Oncodevelopmental Biology and Medicine. Tumour Biol* 1996;17(4):196-219.
7. Nustad K, Onsrud M, Jansson B, Warren D. CA125 – epitopes and molecular size. *Int J Biol Markers* 1998;13:196-200.
8. Moss EL, Hollingworth J, Reynolds TM. The role of CA125 in clinical practice. *J Clin Pathol*. 2005 Mar;58(3):308-12.

9. Colombo N, Peiretti M, Parma G, Lapresa M, Mancari R, Carinelli S, Sessa C, Castiglione M; ESMO Guidelines Working Group. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2010 May;21 Suppl 5:v23-30.
10. Sturgeon CM, Duffy MJ, Walker G. The National Institute for Health and Clinical Excellence (NICE) guidelines for early detection of ovarian cancer: the pivotal role of the clinical laboratory. *Ann Clin Biochem.* 2011 Jul;48(Pt4):295-9.
11. Turpeinen U, Lehtovirta P, Stenman UH. CA 125 determined by three methods in samples from patients with human anti-mouse antibodies (HAMA). *Clin Chem* 1995;41:1667-9. Hilkens, J., et al.: Monoclonal antibodies against human milkfat globule membranes. *Prot Bio/Fluids* 1981;29:813-816.
12. Kufe, D., et al.: Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumor. *Hybridoma* 1984,3(3):223-232.
13. Sekine, H., et al.: Purification and characterization of a high molecular weight glycoprotein detectable in human milk and breast carcinomas. *J Immunol.* 1985;135(5):3610-3615 .
14. Fujino, N., et al.: Clinical evaluation of an immunoradiometric assay for CA 15-3 antigen associated with human mammary carcinomas: Comparison with carcinoembryonic antigen. *Jpn. J. Clin. Oncol.* 1986;46:335-345.
15. Pons-Anticet, D.F.M., et al.: Value of CA 15-3 in the follow-up of breast cancer patients. *Brit. J. Cancer* 1987;55(5):567-569.
16. Duffy MJ, Evoy D, McDermott EW. CA 15-3: uses and limitation as a biomarker for breast cancer. *Clin Chim Acta.* 2010 Dec 14;411(23-24):1869-74.
17. Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P: Colorectal carcinoma antigens detected by hybridoma antibodies. *Somatic Cell Genetics* 5;957-972, 1979.
18. Koprowski H, Herlyn M, Steplewski Z, Sears H: Specific antigen in serum of patients with colon carcinoma. *Science* 212:53-55, 1981.

19. Magnani J, et al: *The Antigen of Tumor-Specific Monoclonal Antibody is a Ganglioside Containing Sialylated Lacto-N-Fucopentaose II. Federation Proceedings*, 41:898; 1982.
20. Del Villano B, Brennan S, Brock P, Bucher C, Liu V, McCleure M, Rake B, Space S, Westrick B, Schoemaker H, Zurawski V Jr: *Radioimmunoassay for Monoclonal Antibody-Defined Tumor Marker CA 19-9. Clin Chem* 29:549-552, 1983.
21. Steinberg W, Gelfand R, Anderson K, Glenn J, Kurtzman SH, Sindelar W, Toskes P: *Comparison of the Sensitivity and Specificity of the CA 19-9 and Carcinoembryonic Antigen Assays in Detecting Cancer of the Pancreas. Gastroenterology* 90:343-349, 1986.
22. Ritts R Jr, Del Villano B, Go VLW, Herberman R, Klug T, Zurawski V Jr: *Initial Clinical Evaluation of an Immunoradiometric Assay for CA 19-9 Using the NCI Serum Bank. Int J Cancer* 33:339-345, 1984.
23. Ohuchi N, Takahashi K, Matoba N, Mori S. *A radioimmunoassay for circulating tumor-associated glycoprotein (TAG-72) using the antigen determinant CA 72-4. Gan To Kagaku Ryoho. 1988 Sep;15(9):2761-6.*
24. Ferroni P, Szpak C, Greiner JW, Simpson JF, Guadagni F, Johnston WW, Colcher D. *CA 72-4 radioimmunoassay in the diagnosis of malignant effusions. Comparison of various tumor markers. Int J Cancer. 1990 Sep 15;46(3):445-51.*
25. Guadagni F, Roselli M, Cosimelli M, Spila A, Cavaliere F, Tedesco M, Arcuri R, Abbolito MR, Casale V, Pericoli MN, Vecchione A, Casciani CU, Greiner JW, Schlom J. *Correlation between tumor-associated glycoprotein 72 mucin levels in tumor and serum of colorectal patients as measured by the quantitative CA 72-4 immunoassay. Cancer Res. 1996 Nov 15;56(22):5293-8.*
26. Reinsberg J, Gast B, Schmolling J, Wagner U, Krebs D. *Specific interference with the determination of the tumour-associated glycoprotein 72 by human anti-idiotypic antibodies formed after treatment with the anti-tumour-associated glycoprotein 72 antibody B72.3. Eur J Clin Chem Clin Biochem. 1994 Sep;32(9):691-6.*
27. Filella X, Molina R, Jo J, Bedini JL, Joseph J, Ballesta AM. *Tumor associated glycoprotein-72 (TAG-72) levels in patients with non-malignant and malignant disease. Bull Cancer. 1992;79(3):271-7. Review.*

28. Kuroki M, Fernsten PD, Wunderlich D, Colcher D, Simpson JF, Poole DJ, Schlom J. Serological mapping of the TAG-72 tumor-associated antigen using 19 distinct monoclonal antibodies. *Cancer Res.* 1990 Aug 15;50(16):4872-9.
29. Motoo Y, Satomura Y, Kawakami H, Watanabe H, Ohta H, Okai T, Sawabu N. Serum levels of tumor-associated glycoprotein (TAG-72) in digestive cancers. *Oncology.* 1990;47(6):456-62.
30. Gero EJ, Colcher D, Ferroni P, Melsheimer R, Giani S, Schlom J, Kaplan P. CA72-4 radioimmunoassay for the detection of the TAG-72 carcinoma-associated antigen in serum of patients. *J Clin Lab Anal.* 1989;3(6):360-9.
31. Sheer DG, Schlom J, Cooper HL. Purification and composition of the human tumor-associated glycoprotein (TAG-72) defined by monoclonal antibodies CC49 and B72.3. *Cancer Res.* 1988 Dec 1;48(23):6811-8.
32. Muraro R, Kuroki M, Wunderlich D, Poole DJ, Colcher D, Thor A, Greiner JW, Simpson JF, Molinolo A, Noguchi P, et al. Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen. *Cancer Res.* 1988 Aug 15;48(16):4588-96.
33. Johnson VG, Schlom J, Paterson AJ, Bennett J, Magnani JL, Colcher D. Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. *Cancer Res.* 1986 Feb;46(2):850-7.
34. Stieber P, Hasholzner U, Bodenmüller H, Nagel D, Sunder-Plassmann L, Dienemann H, et al: CYFRA 21-1 - A new marker in lung cancer. *Cancer*, 72S: 707-713, 1993.
35. Ebert W, Dienemann H, Fateh-Moghadam A, Scheulen M, Konietzko N, Schleich T, et al: Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron specific enolase in lung cancer. Results of an international multicentre study. *Eur J Clin Chem Clin Biochem*, 32: 189-199, 1994.
36. Molina R, Agusti C, Mane JM, Filella X, Joseph J, Gimenez N, et al: CYFRA 21-1 in lung cancer: comparison with CEA, CA 125, SCC and NSE serum levels. *Int J Biol Markers*, 9: 96-101, 1994.

37. Paone G, De Angelis G, Munno R, Pallotta G, Bigioni D, Saltini C, et al: Discriminant analysis on small cell lung cancer and non-small cell lung cancer by means of NSE and CYFRA 21-1. *Eur Respir J* 8: 1136-1140, 1995.
38. Niklinski J, Furman M, Chyczewska E, Chyczewski L, Rogowski F, Laudanski J: Diagnostic and prognostic value of the new tumour marker CYFRA 21-1 in patients with squamous cell lung cancer. *Eur Resp J* 8: 291-294, 1995.
39. Scheulen ME, Klanig H, Wiefelspütz JK, Kšmper P, Wagner B, Konietzko N, et al: Pre-therapeutic evaluation of cytokeratin fragment 19 (CYFRA 21-1) in 240 patients with lung cancer in comparison to CEA, NSE, SCC-Ag, TPA and TPS. *Tumordiagn Ther* 18: 14-19, 1997.
40. Stieber P, Zimmermann A, Reinmiedl J, Müller C, Hoffmann, H Dienemann H. CYFRA 21-1 in the early diagnosis of recurrent disease in non-small cell lung carcinomas (NSCLC). *Anticancer Res* 19: 2665-2668, 1999.
41. Seregini E, Foa P, Bogni A, Botti C, Cataldo I, Sala M, et al. Evaluation of the soluble fragments of cytokeratin 19 (CK19) in non-small cell lung cancer (NSCLC): Comparison with TPA, CEA, Scc and NSE. *Oncol Reports* 3: 95-101, 1996.
42. *Clin Lab.* 2011;57(11-12):1011-4. CYFRA 21-1 as a tool for distant metastasis detection in lung cancer. Cabrera-Alarcon JL, Carrillo-Vico A, Santotoribio JD, Leon-Justel A, Sanchez-Gil R, Gonzalez-Castro A, Guerrero JM.
43. *Clin Lung Cancer.* 2011 May;12(3):172-9. Epub 2011 Apr 24. Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC). Cedrés S, Nuñez I, Longo M, Martinez P, Checa E, Torrejón D, Felip E.
44. *Lung Cancer.* 2011 Oct;74(1):112-7. Epub 2011 Mar 12. Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer. Hanagiri T, Sugaya M, Takenaka M, Oka S, Baba T, Shigematsu Y, Nagata Y, Shimokawa H, Uramoto H, Takenoyama M, Yasumoto K, Tanaka F.
45. *Br J Cancer.* 2010 Oct 12;103(8):1221-8. Epub 2010 Sep 21. A multi-analyte serum test for the detection of non-small cell lung cancer. Farlow EC, Vercillo MS, Coon JS, Basu S, Kim AW, Faber LP, Warren WH, Bonomi P, Liptay MJ, Borgia JA.